Compare ARK Innovation ETF (ARKK) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Innovation ETF vs State Street SPDR S&P Biotech ETF — how do they compare? ARK Innovation ETF trades at $79.65, while State Street SPDR S&P Biotech ETF trades at $158.6. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, ARK Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKK | XBI | |
|---|---|---|
52-Week High | $92.50 | $164.28 |
52-Week Low | $63.52 | $85.16 |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARK Innovation ETF (ARKK) trades at $80.25, down 1.58% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The ETF has gained about 2% year-to-date through late June, sitting near its pivot point of $81. Recent news highlights Cathie Wood's continued stock purchases during pullbacks while the fund faces criticism for its 0.75% expense ratio and underperformance relative to broader tech markets.
The outlook remains mixed with strong technical momentum but fundamental concerns about fees and concentrated exposure to volatile innovation stocks. Key risks include Tesla's 10% weighting creating single-stock vulnerability and the fund's history of 37.88% losses over five years despite recent investor interest resurgence.
XBI, the SPDR S&P Biotech ETF, trades at $159.03, down 3.2% over the past day amid a broader market pullback, though it remains in a strong uptrend with a 17% gain over the past month. Technical indicators are bullish overall, but RSI levels suggest overbought conditions. The ETF's equal-weight exposure to biotech stocks drives high volatility and significant upside during sector rallies, with recent news highlighting booming biotech M&A and AI-driven drug discovery as key catalysts.
The outlook for XBI is positive given sector momentum and favorable deal activity, though its high beta and reliance on small- to mid-cap biotech stocks pose risks during market downturns. Analyst sentiment is neutral with a single hold rating, reflecting caution amid elevated valuations. Investors should weigh the sector's growth potential against inherent volatility and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Innovation ETF
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
